
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics is facing some risks to downside like intense competition, share loss and price erosion, and FDA regulation of LDTs. However, with the company's strong portfolio of molecular tests and potential for growth through new product launches, the analyst remains positive about the company's outlook. The model updates show a steady increase in revenue and EPS over the next few years, indicating a strong financial future for Myriad Genetics. Additionally, GeneSight, one of the company's key tests, continues to show growth and expansion, providing a solid foundation for revenue growth. Lastly, the company is actively addressing any potential risks through cost-cutting measures and focusing on material ESG factors.
Bears say
Myriad Genetics is facing challenges that are structural and may not be temporary, with limited strategic interest in several business segments and a lack of line of sight to profitable growth that may require divestment of assets. Revenue growth is projected to be slow, and the company may struggle to reach its guidance for the year. Additionally, risks to the Medical and Life Science Tools sector may also impact the company, including reduced research and development budgets and increased dependence on volatile emerging markets.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares